Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
- Conditions
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Irinotecan in Treating Patients With Advanced Cancer of the Stomach
- Conditions
- Interventions
- First Posted Date
- 2004-01-22
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 70
- Registration Number
- NCT00003137
- Locations
- 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States
🇺🇸CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States
Fluorouracil, Irinotecan, Leucovorin, and Cisplatin as First-Line Therapy in Treating Patients With Metastatic Esophageal Cancer
- Conditions
- Locations
- 🇫🇷
Clinique La Casamance, Abugne, France
🇫🇷Hopital Drevon, Dijon, France
🇫🇷Centre Jean Bernard, Le Mans, France
Fluorouracil, Leucovorin, and Irinotecan in Treating Patients With Recurrent or Refractory Metastatic Unresectable Colorectal Cancer
- Conditions
- Locations
- 🇫🇷
Polyclinique De Courlancy, Reims, France
🇫🇷Clinique Armoricaine De Radiologie, Saint Brieuc, France
🇫🇷Clinique Saint Jean, Lyon, France
Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 84
- Registration Number
- NCT00074321
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00073866
- Locations
- 🇺🇸
Silver Cross Hospital, Joliet, Illinois, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸Evanston Northwestern Health Care - Evanston Hospital, Evanston, Illinois, United States
Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine
- Conditions
- First Posted Date
- 2003-11-13
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 134
- Registration Number
- NCT00072852
- Locations
- 🇳🇿
Pfizer Investigational Site, Wellington, New Zealand
Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-11-05
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 78
- Registration Number
- NCT00072527
- Locations
- 🇺🇸
McDonough District Hospital, Macomb, Illinois, United States
🇺🇸Hudner Oncology Center at Saint Anne's Hospital, Fall River, Massachusetts, United States
🇺🇸Saint Luke's Hospital, Chesterfield, Missouri, United States
S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00070434
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
- Conditions
- First Posted Date
- 2003-10-01
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00004922
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.